61. Emphysema Treatment Information Guide , causes, symptoms and treatments of emphysema is in this informationguide presented by University of Maryland Medicine. emphysema....... http://www.emphysematreatment.org/

Emphysema w elcome to the Emphysema Guide , presented by University of Maryland Medicine Description Treatments Resources Description What is emphysema? Emphysema, short for pulmonary emphysema, is a chronic lung condition in which alveoli, or air sacs, may be: destroyed narrowed collapsed stretched over-inflated Over-inflation of the air-sacs is a result of a breakdown of the walls of the alveoli, and causes a decrease in respiratory function and breathlessness. Damage to the air sacs is irreversible and results in permanent "holes" in the tissues of the lower lungs. Causes Emphysema does not develop suddenly, but occurs very gradually. The lung has a system of elastic fibers that allow the lungs to expand and contract. Pulmonary emphysema occurs when a breakdown in the chemical balance that protects the lungs against the destruction of the elastic fibers occurs. There are a number of reasons for the breakdown in chemical balance: smoking exposure to air pollution irritating fumes and dusts on the job a rare inherited form of the disease called alpha 1-antitrypsin (AAT) deficiency-related pulmonary emphysema, or early onset pulmonary emphysema

62. Specimen 156.9 Lung Emphysema ( Smoker's Lung ) From a library of medical images, a lung with emphysema ("smoker's lung").Category Health Addictions Substance Abuse Tobacco Effects......Specimen 156.9 Lung emphysema ( Smoker's Lung ). This specimen shows a smoker'slung with cystic spaces (emphysema) due to destruction of airsac walls. http://www.med.unsw.edu.au/pathology/Pathmus/F0839044.htm

Specimen 156.9 Lung : Emphysema ("Smoker's Lung") History of Illness Description of Specimen This specimen shows a smoker's lung with cystic spaces (emphysema) due to destruction of airsac walls. Use the left mouse button to click on areas of interest. Click on a "hotspot", and a brief description will appear in a frame to right of screen. Return to index of images Return to Museum of Human Disease Page

63. Aventis Behring Announces FDA ‘Fast Track’ Designation For Inherited Emphysema FDA) has granted Fast Track review status for the development of a potential intravenoustreatment for Alpha1 Antitrypsin Deficiency (A1AD) related emphysema. http://www.aventisbehring.com/AventisBehring/NewsAndEvents/alphaone.asp

Your Contact: Kim Cayz Aventis Behring Announces FDA ‘Fast Track’ Designation for Inherited Emphysema Treatment King of Prussia, PA, December 20, 2000 – Aventis Behring L.L.C. announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track review status for the development of a potential intravenous treatment for Alpha-1 Antitrypsin Deficiency (A1AD) related emphysema. The investigational drug is Alpha1 Proteinase Inhibitor IV (Human), which is currently being studied in Phase III clinical trials. Alpha-1 Antitrypsin Deficiency affects approximately 100,000 Americans, according to the Alpha One Foundation, a not-for-profit organization dedicated to increasing the awareness and early diagnosis of this life-threatening genetic disorder. A1AD may affect both the structure and the function of the lungs and can lead to chronic emphysema and premature death if left untreated. “Alpha-1 Antitrypsin Deficiency is a serious hereditary condition and as a result, the FDA has determined that this treatment warrants an accelerated clinical development and review period,” said Dr. Ruedi Waeger, CEO of Aventis Behring, L.L.C. “We are pleased with the Fast Track designation, and believe that the FDA supports our research efforts in patients associated with A1AD related emphysema.” “We are pleased that the FDA has recognized the critical situation shared by the Alpha -1 community. Alpha-1 Antitrypsin Deficiency is one of the most under-recognized and underdiagnosed hereditary disorders in the United States,” said John W. Walsh, President and CEO of the Alpha One Foundation. “We are extremely impressed with Aventis Behring's commitment to help alleviate the unmet medical needs of Alpha-1 patients.”

64. Copd, Emphysema, Cystic Fibrosis, Breathing Aids Product resources for asthma sufferersCategory Shopping Health Respiratory Conditions Asthma......Products resources for COPD,asthma, emphysema,cystic fibrosis, bronchiectasis.Featuring the Breather 510K (FDA) approved . 8034 http://www.betterairways.com/

Welcome. This site is for people with COPD (chronic obstructive pulmonary disease), emphysema, chronic bronchitis, and asthma. We offer affordable products to improve your breathing. When you can't breathe, nothing else matters Whether your prognosis is emphysema, or you're a child or teenager with asthma, or a smoker who wants to quit, the Breather will help you Our premiers product, the Breather, is the only patented, FDA 510(k) approved breathing device with both inspiratory and expiratory resistance. Breathing is the most "taken for granted" function of the body, until we lose it. You can now easily include breathing retraining in your daily routine. The Breather has been recommended by many health care practitioners and sports' trainers. There are so many applications for its use and for varying types of patients and for anyone who recognizes the restorative value of deep breathing. Respiratory therapists, physical therapists, cardiopulmonary nurses, speech pathologists, and holistic health care providers all know the value of proper breathing. In addition to treating COPD, many professionals use the Breather for cystic fibrosis, bronchiectasis, asbestosis, black lung disease, dysarthria (imperfect phonation), dysphagia (difficulty in swallowing), post polio syndrome, cerebrovascular accidents (stroke), quadriplegia, post operatively - especially for abdominal surgeries, and any time a person is short of breath or suffers from panic attacks.

65. The MSDS HyperGlossary: Emphysema emphysema. Definition. Smoking is by far the major risk factor (cause) of emphysema,accounting for 82% of COPD cases according to the American Lung Association. http://www.ilpi.com/msds/ref/emphysema.html

Safety Emporium for all your lab and safety needs Emetic Glossary Index Energy Units MSDS Topics Free Sites FAQ's Regulations Glossary Software Suppliers Books Forum ... Contact Understand your MSDS with the MS-Demystifier Search ALL our MSDS info Emphysema Definition Emphysema is a disease in which the alveoli (tiny air sacs) of the lung become damaged. This results in a decrease in respiratory function (the lungs don't work as well) and often, breathlessness. Early symptoms of emphysema include shortness of breath and cough. Emphysema and chronic bronchitis together comprise chronic obstructive pulmonary disease (COPD) Additional Info Smoking is by far the major risk factor (cause) of emphysema, accounting for 82% of COPD cases according to the American Lung Association. Certain individuals are also genetically disposed towards emphysema; this form is called alpha 1-antitrypsin (AAT) emphysema. Extensive smoking can lead to irreparable lung damage, even if you quit smoking. In these cases, the condition is not likely to improve and death by respiratory or cardiac (heart) failure is the inevitable outcome (months to years). Is smoking worth three years on a respirator as your body wastes away? Quit today, if not for yourself then for your friends and families who don't want to deal with that. Books Available "The Chronic Bronchitis and Emphysema Handbook", Paperback, 318 pages, 2000. Estimated price $11.17.

66. Respiratory Research | Abstract | Myosin Heavy Chain And Physiological Adaptatio Myosin heavy chain and physiological adaptation of the rat diaphragm in elastaseinducedemphysema Dong Kwan Kim 1 , 6 , Jianliang Zhu 1 , Benjamin W Kozyak 1 http://respiratory-research.com/content/4/1/1/abstract

Welcome guest user home issues articles reports ... Issue 1 Viewing options Abstract Full text PDF Other links: E-mail to a friend Download references Post a comment PubMed record ... Related articles in PubMed Search PubMed For Kim DK Zhu J Kozyak BW Burkman JM ... Shrager JB Key E-mail Corresponding author Research article Myosin heavy chain and physiological adaptation of the rat diaphragm in elastase-induced emphysema Dong Kwan Kim Jianliang Zhu Benjamin W Kozyak James M Burkman Neal A Rubinstein Edward B Lankford Hansell H Stedman Taitan Nguyen Sanford Levine and Joseph B Shrager Department of Surgery, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA Pennsylvania Muscle Institute, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA Department of Surgery, Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA Department of Medicine, Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA Present address: Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

67. The Breathing Space -- Information For Chronic Bronchitis, Emphysema, Or Asthma Information about medications, stopping smoking, and living better with chronic obstructive pulmonary Category Health Conditions and Diseases......If someone you know has chronic bronchitis or emphysema, The Breathing Space is fullof information about medications, stopping smoking, and living better with http://www.combivent.com/fam_index.htm

The COPD Library The lungs in sickness and in health. About 16 million people in the United States have chronic obstructive pulmonary disease (COPD) . If you know one of them and want to learn more, this site is for you, whether you are a family member or a friend. Your help, along with proper diagnosis, treatment, and education, can mean a lot to a person with COPD. You can help maintain and improve your loved one's health and quality of life. The more you know about COPD, the more you can contribute to your family member or friend's health. We have designed this website to give you the information you need as directly and easily as possible. The COPD Library is a good place to start. And don't miss the Magazine Stand for two free publications full of useful information. The material on this website in no way replaces the advice of a physician. A person with COPD should consult a physician for personalized medical advice. Please feel free to print out and copy any or all of these materials to share with someone you care about. If you have questions or comments, please fill out our feedback form.

68. Boston University News Release RETINOIC ACID BEING TESTED AS POSSIBLE emphysema TREATMENT. (Boston,Mass.) — Boston University School of Medicine (BUSM) researchers http://www.bu.edu/news/releases/2001/4-24-emphysema.htm

News Release Return to News Releases Contact: Gina DiGravio, 617-638-8491, gina.digravio@bmc.org RETINOIC ACID BEING TESTED AS POSSIBLE EMPHYSEMA TREATMENT "We hope this study will provide us with a new option that will relieve symptoms and improve quality of life for emphysema patients in our community." Emphysema is a lung disease that affects millions Americans, most of them longtime smokers over the age of 45. Emphysema and other forms of chronic obstructive pulmonary disease (COPD) are the fourth leading cause of death in the United States each year and account for more than $2.5 billion in annual health care costs. The other centers participating in FORTE include: Columbia University, New York City; University of California, Los Angeles; University of California, San Diego; and University of Pittsburgh. April 24, 2001 Boston University Questions Office of Public Relations 25 Buick Street Boston, MA 02215

69. Pneumothorax, Pneumomediastinum And Pulmonary Interstitial Emphysema Information on pneumothorax, pneumomediastinum and pulmonary interstitialemphysema in the newborn written by health professionals for parents. http://www.pediatrics.wisc.edu/childrenshosp/parents_of_preemies/pppie.html

Pneumothorax, Pneumomediastinum and Pulmonary Interstitial Emphysema What are Pneumothorax, Pneumomediastinum and Pulmonary Interstitial Emphysema (PIE)? Normally the air that we breathe goes down the trachea (windpipe) to a series of branches of the windpipe called bronchi. The air then goes to the air sacs where oxygen is delivered to the blood and carbon dioxide is released. If the air sacs become overfilled with air, the air can break out of the air sacs and get into spaces where it should not be. This condition is sometimes referred to as AIR LEAK and includes the following: PNEUMOTHORAX where the air is trapped inside the chest between the chest wall and the lung, causing the lung to collapse. PNEUMOMEDIASTINUM where air is trapped in the middle part of the chest. PULMONARY INTERSTITIAL EMPHYSEMA (PIE) where air is trapped between the tiny air sacs, encircling the smallest blood vessels and bronchi. Less commonly, air can encircle the heart, (Pneumopericardium), get under the skin, (Subcutaneous Emphysema), leak into the abdomen (Pneumoperitoneum) or surround the kidneys (Pneumoretroperitoneum). A baby often has more than one form of air leak. For example, PIE can progress to pneumomediastinum and/or pneumothorax. Which babies get air leak?

70. Mayo Clinic - Clinical Trial: National Emphysema Treatment Trial (NETT) National emphysema Treatment Trial (NETT). To do this, researchers will comparethe benefits and risks of medical treatment for emphysema and; http://www.mayo.edu/research/pcrc/trial_79.html

National Emphysema Treatment Trial (NETT) Research PCRC Directory Clinical Trials ... Publications A closed clinical trial Mayo NETT appointment number: Lung Volume Reduction Surgery for Emphysema The National Emphysema Treatment Trial is a clinical trial to learn about the benefits and risks of lung volume reduction surgery. To do this, researchers will compare the benefits and risks of: medical treatment for emphysema and medical treatment plus lung volume reduction surgery. People who take part in NETT will be assigned to one of these treatment groups. NETT staff will follow patient's response to treatment for up to 5 years. Lung Volume Reduction Surgery for Emphysema has been shown to relieve shortness of breath and improve the quality of life of some patients with severe emphysema. While some patients appear to benefit from this procedure, others do not. Questions remain as to the optimal patient selection criteria, the mechanisms of improvement, and the long term effects of the procedure. Whether most patients with emphysema would benefit from this procedure is unknown. The National Institutes of Health and the Health Care Financing Administration are jointly sponsoring a large multicenter clinical study comparing volume reduction surgery for emphysema with standard intensive medical therapy. This study is called the National Emphysema Treatment Trial (NETT). The Mayo Clinic has been designated as one of the clinical centers collaborating with other centers across the United States in this important trial. This trial is being done because it is not known whether volume reduction surgery for emphysema or conventional medical treatment is better for most patients. This trial will take several years to be completed.

71. Hereditary Emphysema (Alpha-One) Support Group This Hereditary emphysema (AlphaOne) support group meets monthly at FroedtertHospital. Subscribe now . Hereditary emphysema (Alpha-One) Support Group. http://healthlink.mcw.edu/article/929049213.html

Search Articles: search tips Please Take the HealthLink Survey Email this article Print this article Find related articles: By topic: By keywords: Receive Health Link via email! Subscribe now >> Hereditary Emphysema (Alpha-One) Support Group The Hereditary Emphysema (Alpha-One) support group for individuals with alpha-1 antitrypsin deficiency disease meets: When: Monthly on the second Thursday from 7:00 to 9:00 p.m.. For more information, please call (414) 805-2880. Community Education Department Froedtert Memorial Lutheran Hospital How to get to Froedtert Article Created: 1999-05-01 Article Updated: 2001-01-08 Home About HealthLink Medical College of Wisconsin Clinical Trials ... Privacy

72. RSNA News: Helium Imaging Improves Diagnosis Of Pulmonary Emphysema page. July 2002. Quick links. View Images. RSNA News July 2002.Helium Imaging Improves Diagnosis of Pulmonary emphysema DimitriyA http://www.rsna.org/publications/rsnanews/july02/emphysema-1.html

Radiological Society of North America, Inc. Founded in 1915 SiteTools Search Sitemap FAQ Tasks Classifieds Contact Home Navigation trail: Home Publications RSNA News RSNA News July 2002 ... July 2002 Quick links View Images RSNA News - July 2002 Helium Imaging Improves Diagnosis of Pulmonary Emphysema Dimitriy A. Yablonskiy, Ph.D. Mallinckrodt Institute of Radiology, Washington University School of Medicine A major advance in lung imaging may add momentum to the long struggle in the evaluation and treatment of emphysema and other chronic lung diseases. "CT doesn't give you information at the level of the alveoli, which is the basic structure of the lung. Nor does it distinguish between ventilated and unventilated areas of the lungs. CT can tell you about the decrease in lung tissue density, but by itself, cannot tell you about the microstructure of the lung," says Dr. Yablonskiy, a professor of physics and an assistant professor of radiology at the Mallinckrodt Institute of Radiology at Washington University School of Medicine in St. Louis. About five years ago, scientists suggested the idea of having patients inhale hyperpolarized helium while being imaged by MR, and then measuring the distance helium atoms traveled inside the lung. "Helium is much less dense than water. Because the signals that we measure with MRI are proportional to the [spin] density of the substance, we must hyperpolarize the nuclear spins of the gas prior to imaging."

73. Aventis Behring Ltd Aventis Behring Announces Promising Results of a Phase IB Clinical Trialfor Inhaleable Alpha1Antitrypsin for Hereditary emphysema Patients. http://www.aventisbehring.co.uk/news/default.asp

The latest news from the world of Aventis Behring and the haemophilia community The information in these news pages is frequently updated, so why not add the Aventis Behring UK homepage to your favourites or bookmarks to keep up-to-date with all the latest news and developments in the haemophilia world. As well as the latest news, you can browse our archives , see what's new on the site or look at forthcoming medical conferences worldwide. Aventis Behring Ltd is not responsible for the content of external internet sites. News and information from the Aventis Behring website in the United States Change in Storage Requirements for Helixate® NexGen Aventis Behring - 1st August 2001 Regulatory Affairs Manager Aventis Behring Limited Aventis House Market Place Haywards Heath West Sussex RH16 1DB - UK United Kingdom Tel: 01444 447400 Fax: 01444 447401 Aventis Behring Announces Promising Results of a Phase IB Clinical Trial for Inhaleable Alpha1-Antitrypsin for Hereditary Emphysema Patients. Aventis, King of Prussia - 8th June 2001

74. BBC NEWS | Health | Medical Notes | Emphysema emphysema is a progressive lung condition which leaves sufferers strugglingfor breath. Friday, 24 September, 1999, 1427 GMT 1527 UK emphysema. http://news.bbc.co.uk/1/low/health/medical_notes/456591.stm

BBC NEWS News Front Page World UK England ... Talking Point Health Contents: Medical notes Friday, 24 September, 1999, 14:27 GMT 15:27 UK Emphysema Emphysema is a progressive lung condition which leaves sufferers struggling for breath. Miners who say their job left them with irreversible emphysema have been at court fighting for compensation from their former employers. Emphysema is caused by gradual damage to the structure of the lungs, which makes it harder to exhale. The tiny air sacs in the lungs called alveoli, through which oxygen is absorbed into the bloodstream, lose their natural elasticity, meaning spent air is pushed back out into the lungs. This leaves the lungs feeling continually over full, and it is a struggle for sufferers to force air in and out. This eventually means that the body is not getting enough oxygen, leading to fatigue and weight loss. Although it can start simply as mild breathlessness during exercise and a persistent cough, it can leave sufferers housebound and reliant on oxygen supplies, and eventually contribute to death. Smoking causes it Emphysema usually affects older people as it is due to culmulative damage over a long period, such as a lifetime of smoking.

75. Emphysema, University Of Pittsburgh Medical Center, Pittsburgh, PA, USA Comprehensive information about the causes, symptoms, diagnosis, and treatmentof emphysema from the health care experts at UPMC Health System. http://emphysema.upmc.com/

Emphysema is a condition that makes the act of breathing difficult because the lungs are not able to expand and contract properly. Read more UPMC University of Pittsburgh Schools of the Health Sciences Contact UPMC Supplemental content provided by HealthGate Data Corp

76. Avian Medecine Chronic subcutaneous emphysema following air sac trauma in larger psittacine speciesis corrected by an implanted stent placed at the base of the skull in the http://www.mcallister.com/avian.html

Avian Veterinary Medicine Excerpted from the proceedings of Association of Avian Veterinarians, Chicago, 1988 TEFLON DERMAL STENT FOR THE CORRECTION OF SUBCUTANEOUS EMPHYSEMA James M. Harris, D.V.M. 1961 Mountain Boulevard Oakland, CA 94611 United States of America Chronic subcutaneous emphysema following air sac trauma is frequently encountered in avian species. For the companion avian practitioner, larger psittacine species represent patients that are suitable for corrective measures. Miniaturized techniques might be used in smaller patients. THE STENT: DESCRIPTION AND TECHNIQUE The stent used is machined from solid virgin Teflon by McAllister Technical Services at West 280 Prairie Avenue, Coeur d'Alene, ID 83814, tel: 1-208-772-9527. The unit is 12.7 or 16 mm in diameter with eight pre-drilled holes for suture placement in the subcutaneous flange. The central stem is 1.5 mm deep and 4.5 mm in diameter with a 1.5 mm orifice. The outer rim is 8 mm in diameter, allowing the skin to tuck under the edge and thereby preventing the healing dermis from closing over the implant. The stents are inert and non-reactive. One post-surgical problem has been occasional plugging of the stent with mucous or congealed tissue fluid which is easily removed with a needle. This has occurred a few times post-operatively in some cases, but this problem eventually clears. Post-operative antibiotics have not been used and infected surgical sites have not occurred. To prevent post-surgical plugging in larger psittacines, it might be useful to use a larger stent with a 3 mm orifice and a 16 mm diameter external flange.

77. Disease Category Listing (59): Emphysema Clinical Trials emphysema. California. Carmichael; Delbert Meyer,MD Chronic Bronchitis emphysema. Carmichael; Pulmonary http://www.centerwatch.com/patient/studies/cat59.html

Clinical Trials: Emphysema California Carmichael; Delbert Meyer, M.D. Carmichael; Pulmonary Medicine Associates Long Beach; West Coast Clinical Trials Do you suffer from Chronic Bronchitis, Emphysema or Chronic Obstructive Pulmonary Disease (COPD)? Riverside; Inland Clinical Research, Inc. Do you have Chronic Bronchitis, Emphysema or Chronic Obstructive Pulmonary Disease (COPD)? San Diego; Protocare Trials Pacific Research Network (PRN) Are you or a loved one interested in participating in a clinical trial for Emphysema? Spring Valley; Encompass Clinical Research Colorado Arvada; Western States Clinical Research, Inc. Are you short of breath? Arvada; Western States Clinical Research, Inc. Are you short of breath? Wheat Ridge; Rocky Mountain Center for Clinical Research Connecticut Hartford; Physicians Research Center, Inc. Volunteers needed to participate in a clinical research study to compare the effects of inhaled investigational medications for smokers or ex-smokers suffering from chronic bronchitis and emphysema, also known as COPD - Chronic Obstructive Pulmonary Disease. Florida Largo; Diagnostic Clinic

78. Venuta - Giant Bullous Emphysema Giant Bullous emphysema. Figure 2. Operative view at thoracotomy ofmultiple bullae with underlying lung with diffuse emphysema. http://www.ctsnet.org/doc/6761

CTSNET Experts' Techniques, General Thoracic Experts' Techniques Section Editor: Mark K. Ferguson, M.D. Navigation Menu Patient Selection Operative Steps Preference Card Tips and Pitfalls ... References Giant Bullous Emphysema Federico Venuta, M.D. Associate Professor of Thoracic Surgery University of Rome "La Sapienza" Policlinico Umberto I Department of Thoracic Surgery Rome, Italy Tiziano de Giacomo, M.D. Associate Professor of Surgery Chief, Division of Thoracic and Foregut Surgery Co-Director, Minimally Invasive Surgery Center University of Pittsburgh Medical Center Pittsburgh, Pennsylvania

79. Ask Dr Stoll - Emphysema And Rebounding http://askwaltstollmd.com/rebounding.html

80. Asthma, COPD, Chronic Obstructive Pulmonary Disease, Bronchitis, Chronic Bronchi There are many ways to classify drugs for asthma and COPD. The classification offered here is based Category Health Conditions and Diseases Treatment...... COPD is found mainly in long term smokers. The term COPD comprisestwo similar conditions, chronic bronchitis and emphysema. It http://www.mtsinai.org/pulmonary/books/breathe/ASTHMADR.htm

Updated 2002 Lawrence Martin, M.D., FACP, FCCP Pulmonary Division University Mednet Mentor, Ohio 44060 Associate Professor of Medicine Case Western Reserve University School of Medicine Cleveland, Ohio Return to Pulmonary Division home page Index to all of Dr. Martin's web sites Click here for drugs used to treat rhinitis and sinusitis Go Directly to Drug Classification COMMENT ON CLASSIFICATION. There are many ways to classify drugs for asthma and COPD (chronic obstructive pulmonary disease). The classification offered here is based on their mechanism of action in improving the basic problem (which is airway obstruction) and by their route of administration (oral or pill form, by inhalation, or by injection). Our lungs contain many branching airways that deliver fresh air to the blood. The phrase "drugs for asthma and COPD" means drugs that help open up the airways when they become narrowed due to disease. (Note that these are generally different from medications used to treat upper airway problems (rhinitis and sinusitis); see the link above for a table of those drugs.) Other drugs may be used in people with asthma and COPD, such as antibiotics for infection, but they are not used to directly "open up" the airways. When it comes to drugs for "opening up" the airways, all available medications can be classified by one of two basic mechanisms of action: bronchodilation and anti-inflammatory.

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

Page 4     61-80 of 100    Back | 1  | 2  | 3  | 4  | 5  | Next 20